ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, vol.27, issue.8, pp.1386-1422, 2016. ,
Flash RAS study: RAS testing assessment in patients with metastatic colorectal cancer in 2014, Eur J Cancer, vol.51, p.85, 2015. ,
KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting, PLoS One, vol.9, issue.1, p.85897, 2014. ,
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, vol.15, issue.10, pp.1065-1075, 2014. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, issue.12, pp.1722-1731, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014. ,
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, issue.4, pp.430-435, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168071
Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat Rev Cancer, vol.17, issue.4, pp.223-238, 2017. ,
Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, J Thorac Oncol, vol.9, issue.9, pp.1345-1353, 2014. ,
Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA, Clin Chem, vol.62, issue.11, pp.1492-1503, 2016. ,
A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker, Clin Chem, vol.62, issue.8, pp.1129-1139, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02295782
Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study), Clin Cancer Res, vol.23, issue.18, pp.5416-5425, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299521
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients, Ann Oncol, vol.28, issue.6, pp.1325-1332, 2017. ,
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment, Ann Oncol, vol.28, issue.9, pp.2149-2159, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01682168
Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution, Nat Commun, vol.8, issue.1, 1998. ,
Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience, PLoS One, vol.8, p.68945, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00974911
Concordance of blood-and tumorbased detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer, Ann Oncol, vol.28, issue.6, pp.1294-1301, 2017. ,
Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker, Clin Cancer Res, vol.23, issue.1, pp.116-123, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01458933